Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal cytarabine + lomustine + radiotherapy
- Development stage
- Unknown
- Lead developer
- University Hospital Bonn
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intrathecal, Oral, Radiation
01
Overview
The DepoRaCe regimen is a multimodal combination therapy evaluated in a Phase 1 clinical trial by the University Hospital, Bonn, specifically for the treatment of leptomeningeal metastasis from malignant melanoma. This therapeutic protocol combines intrathecal liposomal cytarabine (DepoCyte), systemic lomustine (CCNU), and whole-brain radiotherapy. Liposomal cytarabine is an antimetabolite that provides sustained-release chemotherapy directly into the cerebrospinal fluid, inhibiting DNA synthesis in meningeal tumor cells. Lomustine is a lipophilic nitrosourea alkylating agent that effectively crosses the blood-brain barrier to induce DNA cross-linking. The addition of brain radiotherapy provides synergistic cytotoxic effects through ionizing radiation-induced DNA damage. The regimen was designed to address the poor prognosis of melanoma-related leptomeningeal disease by targeting tumor cells through multiple mechanisms of action and delivery routes.
- Brand names
- DepoCyteGleostine
- Other names
- DepoRaCe regimenliposomal cytarabine + CCNU + WBRT
02
Targets
DNA
Beyond the preview
Go deeper on liposomal cytarabine + lomustine + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal cytarabine + lomustine + radiotherapy.